Pharmacokinetics (PK)

项目总结/摘要（药代动力学共享资源） 药代动力学共享资源（PK-SR）成立于2009年，自2009年以来一直由CCSG资助。 2012. PK-SR由联合董事孙杜新（DT）和阿米特派（DT）领导，有11名全职工作人员， 8台LC-MS仪器。PK-SR在推进药物发现、药物优化和药物代谢方面发挥着关键作用。 新型抗癌疗法的临床转化。PK-SR拥有13年的支持领先记录 基于体外和体内ADME的癌症药物发现/优化中的化合物选择（吸收， 分布、代谢和排泄）和临床前药代动力学（PK）平台。强大的生物分析 SR的PK知识也支持进行I/II期临床研究的研究者的临床PK需求 在患者中进行试验。Rogel癌症中心（Rogel）成员受益于所提供的资源和战略建议。 PK-SR在指导关键实验决策方面发挥着关键作用，有助于简化研究， 以最低的成本获取信息。这种方法为Rogel领导的重大科学进步做出了贡献 成员PK-SR基于学术研究组织框架运作，以快速告知去或不去- 决定由Rogel成员调查的关键化合物。PK-SR还在联合赠款方面进行合作 和专利申请，并帮助产生高影响力的出版物。

PROJECT SUMMARY/ABSTRACT (PHARMACOKINETICS SHARED RESOURCE) The Pharmacokinetics Shared Resource (PK-SR) was founded in 2009 and has been funded by the CCSG since 2012. PK-SR is led by Co-Directors Duxin Sun (DT) and Amit Pai (DT) with eleven full time staff members and eight LC-MS instruments. PK-SR plays a pivotal role in advancing the drug discovery, drug optimization, and clinical translation of novel anti-cancer therapeutics. PK-SR has a thirteen-year track record of supporting lead compound selection in cancer drug discovery/optimization based on in vitro and in vivo ADME (absorption, distribution, metabolism, and excretion) and preclinical pharmacokinetic (PK) platforms. The strong bioanalytical and PK knowledge of the SR also supports the clinical PK needs of investigators performing phase I/II clinical trials in patients. Rogel Cancer Center (Rogel) members benefit from the resources and strategic advice offered. PK-SR plays a pivotal role in guiding key experimental decisions to help streamline studies to maximize information gain at the lowest cost. This approach has contributed to major scientific advancements led by Rogel members. PK-SR operates based on an academic research organization framework to rapidly inform go or no- go decisions on key compounds under investigation by Rogel members. PK-SR also collaborates on joint grant and patent applications and helps generate high-impact publications.